Rebecca Mazahreh, Marsha L Mason, John J Gosink, Devra J Olson, Robert Thurman, Christopher Hale, Lori Westendorf, Thomas A Pires, Christopher I Leiske, Markus Carlson, Liem T Nguyen, Julia H Cochran, Nicole M Okeley, Roma Yumul, Steven Jin, Ivan J Stone, Disha Sahetya, Albina Nesterova, Sean Allred, Kelly M Hensley, Rachael Hu, Robert Lawrence, Timothy S Lewis, Sharsti Sandall
SGN-CD228A is an investigational antibody-drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of a humanized antibody, hL49, with high specificity and affinity for CD228 that is stably conjugated to 8 molecules of the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via a novel glucuronide linker. We performed comprehensive immunohistochemical studies, which corroborated published RNA-seq data and confirmed low CD228 expression in normal tissues and high expression in several cancers, including melanoma, squamous non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer, and pancreatic cancer...
February 7, 2023: Molecular Cancer Therapeutics